| 2017 | A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalanprednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma | 문영철 | Article |
| 2017 | Association between left ventricular function and paraprotein type in patients with multiple myeloma | 이정은 | Article |
| 2018 | Clinicopathological Characteristics of Hyperdiploidy with High-Risk Cytogenetics in Multiple Myeloma | 성주명; 허정원; 문영철 | Article |
| 2020 | Intravenous busulfan and melphalan versus high-dose melphalan as a conditioning regimen for early autologous stem cell transplantation in patients with multiple myeloma: a propensity score-matched analysis | 문영철 | Article |
| 2022 | Meibomian Gland Dysfunction Associated with Bortezomib in a Multiple Myeloma Patient | 한경은; 전루민 | Article |
| 2018 | Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150) | 문영철 | Article |
| 2022 | Relapse with plasmacytoma after upfront autologous stem cell transplantation in multiple myeloma | 문영철 | Article |
| 2016 | The clinical impact of thalidomide maintenance after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in real clinical practice of Korea | 문영철 | Article |
| 2018 | The Derived Neutrophil-to-Lymphocyte Ratio Is an Independent Prognostic Factor in Transplantation Ineligible Patients with Multiple Myeloma | 문영철 | Article |
| 2020 | The effectiveness and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world clinical practice: a study of the Korean Multiple Myeloma Working Party (KMMWP-151 study) | 문영철 | Article |
| 2015 | The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea | 문영철 | Article |
| 2015 | Varicella-zoster virus-specific cell-mediated immunity and herpes zoster development in multiple myeloma patients receiving bortezomib- or thalidomide-based chemotherapy | 문영철 | Article |
